Astria Therapeutics, Inc. — Director's Dealing 2016

Oct 5, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: CATABASIS PHARMACEUTICALS INC (CATB)
CIK: 0001454789
Period of Report: 2016-10-03

Reporting Person: Nichols Andrew John (Chief Scientific Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$6.81	2024-03-18	Common Stock (58365)		Direct
Stock Option (right to buy)	$11.05	2025-03-25	Common Stock (2723)		Direct
Stock Option (right to buy)	$11.05	2025-04-29	Common Stock (7782)		Direct
Stock Option (right to buy)	$4.57	2026-02-10	Common Stock (26000)		Direct
Sock Option (right to buy)	$4.31	2026-09-07	Common Stock (40000)		Direct

Footnotes

F1: This option is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 16, 2014 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.

F2: This option is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversay of March 26, 2015 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.

F3: This option is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of June 1, 2015 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.

F4: This option is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 11, 2016 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.

F5: This option is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of September 8, 2016 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.